Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599012142> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2599012142 abstract "TPS11121 Background: We have developed 64 Cu-DOTA-trastuzumab for PET imaging of HER2-positive breast cancer. We have determined that administering trastuzumab (45 mg) prior to 64 Cu-DOTA-trastuzumab sharply reduces liver uptake of the radiotracer. We are now testing whether tumor uptake of 64 Cu-DOTA-trastuzumab correlates with variable IHC staining in women with advanced breast cancer. Methods: Eligibility criteria included biopsy confirmation of metastatic disease that was HER2 1+, 2+, or 3+ by IHC, no anti-HER therapy within the prior 4 mo, and at least 1 non-hepatic site of metastasis > 20 mm outside the biopsy site. Staging workup included 18 F-FDG PET-CT. Patients received 45 mg of cold trastuzumab prior to 64 Cu-DOTA-trastuzumab. PET-CT scans were obtained at 21-25 h (Day 1) and 47-48 h (Day 2) over axial fields of view chosen in reference to 18 F-FDG. Uptake in prominent lesions was measured in terms of maximum single-voxel SUV (SUV max ). Lesions identified on CT and judged to have image intensity > adjacent tissue by an expert radiologist were considered positive on PET. Results: Fourteen women (median age 56, range 35-75 y) have undergone imaging. HER2 status by IHC was 3+ in 9 pts., 2+ in 5 and 1+ in 1. Two women with IHC 2+ disease were FISH+. In the patients considered clinically HER2 positive (IHC 3+ or 2+, FISH+), 64 Cu-DOTA-trastuzumab sensitivity was 75 and 90%, respectively, on Days 1 and 2, compared with 94% for 18 F-FDG. Tumor uptake of 64 Cu-DOTA-trastuzumab was also readily visualized in HER2-negative patients (measured detection sensitivity 90%). There were no false positive findings with 64 Cu-DOTA-trastuzumab. Lesion uptake of 64 Cu-DOTA-trastuzumab was higher in HER2+ than in HER2- patients (SUV max mean ± sem: Day 1 8.9±0.6 vs 4.3±0.2; Day 2 9.9±0.8 vs 5.4±0.3, p < 0.001). Conclusions: 64 Cu-DOTA-trastuzumab PET visualizes HER2 1+, 2+ and 3+ metastatic breast cancer with high sensitivity and specificity. Tumor uptake of 64 Cu-DOTA-trastuzumab-PET in IHC 1+ and 2+ patients implies possible benefit from anti-HER2 therapies for individuals whose cancers are currently considered HER2 negative. Research Support: DOD1024511. Clinical trial information: NCT01093612." @default.
- W2599012142 created "2017-04-07" @default.
- W2599012142 creator A5005344580 @default.
- W2599012142 creator A5021986503 @default.
- W2599012142 creator A5022121581 @default.
- W2599012142 creator A5031409271 @default.
- W2599012142 creator A5040475694 @default.
- W2599012142 creator A5069137498 @default.
- W2599012142 creator A5072320451 @default.
- W2599012142 creator A5073449436 @default.
- W2599012142 creator A5082864167 @default.
- W2599012142 date "2013-05-20" @default.
- W2599012142 modified "2023-09-22" @default.
- W2599012142 title "Correlation of 64Cu-DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC)." @default.
- W2599012142 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps11121" @default.
- W2599012142 hasPublicationYear "2013" @default.
- W2599012142 type Work @default.
- W2599012142 sameAs 2599012142 @default.
- W2599012142 citedByCount "0" @default.
- W2599012142 crossrefType "journal-article" @default.
- W2599012142 hasAuthorship W2599012142A5005344580 @default.
- W2599012142 hasAuthorship W2599012142A5021986503 @default.
- W2599012142 hasAuthorship W2599012142A5022121581 @default.
- W2599012142 hasAuthorship W2599012142A5031409271 @default.
- W2599012142 hasAuthorship W2599012142A5040475694 @default.
- W2599012142 hasAuthorship W2599012142A5069137498 @default.
- W2599012142 hasAuthorship W2599012142A5072320451 @default.
- W2599012142 hasAuthorship W2599012142A5073449436 @default.
- W2599012142 hasAuthorship W2599012142A5082864167 @default.
- W2599012142 hasConcept C121608353 @default.
- W2599012142 hasConcept C126322002 @default.
- W2599012142 hasConcept C126838900 @default.
- W2599012142 hasConcept C142724271 @default.
- W2599012142 hasConcept C150903083 @default.
- W2599012142 hasConcept C204232928 @default.
- W2599012142 hasConcept C207001950 @default.
- W2599012142 hasConcept C2775842073 @default.
- W2599012142 hasConcept C2779786085 @default.
- W2599012142 hasConcept C2779931791 @default.
- W2599012142 hasConcept C2989005 @default.
- W2599012142 hasConcept C530470458 @default.
- W2599012142 hasConcept C71924100 @default.
- W2599012142 hasConcept C86803240 @default.
- W2599012142 hasConceptScore W2599012142C121608353 @default.
- W2599012142 hasConceptScore W2599012142C126322002 @default.
- W2599012142 hasConceptScore W2599012142C126838900 @default.
- W2599012142 hasConceptScore W2599012142C142724271 @default.
- W2599012142 hasConceptScore W2599012142C150903083 @default.
- W2599012142 hasConceptScore W2599012142C204232928 @default.
- W2599012142 hasConceptScore W2599012142C207001950 @default.
- W2599012142 hasConceptScore W2599012142C2775842073 @default.
- W2599012142 hasConceptScore W2599012142C2779786085 @default.
- W2599012142 hasConceptScore W2599012142C2779931791 @default.
- W2599012142 hasConceptScore W2599012142C2989005 @default.
- W2599012142 hasConceptScore W2599012142C530470458 @default.
- W2599012142 hasConceptScore W2599012142C71924100 @default.
- W2599012142 hasConceptScore W2599012142C86803240 @default.
- W2599012142 hasLocation W25990121421 @default.
- W2599012142 hasOpenAccess W2599012142 @default.
- W2599012142 hasPrimaryLocation W25990121421 @default.
- W2599012142 hasRelatedWork W1930021173 @default.
- W2599012142 hasRelatedWork W1964836353 @default.
- W2599012142 hasRelatedWork W1978863320 @default.
- W2599012142 hasRelatedWork W2067265270 @default.
- W2599012142 hasRelatedWork W2082185964 @default.
- W2599012142 hasRelatedWork W2117793816 @default.
- W2599012142 hasRelatedWork W2144467667 @default.
- W2599012142 hasRelatedWork W2180976638 @default.
- W2599012142 hasRelatedWork W2330668380 @default.
- W2599012142 hasRelatedWork W2345989459 @default.
- W2599012142 hasRelatedWork W2591509828 @default.
- W2599012142 hasRelatedWork W2616675900 @default.
- W2599012142 hasRelatedWork W2921476576 @default.
- W2599012142 hasRelatedWork W2991335041 @default.
- W2599012142 hasRelatedWork W3000178100 @default.
- W2599012142 hasRelatedWork W3011459709 @default.
- W2599012142 hasRelatedWork W3106645799 @default.
- W2599012142 hasRelatedWork W3171091741 @default.
- W2599012142 hasRelatedWork W3205431215 @default.
- W2599012142 hasRelatedWork W71321029 @default.
- W2599012142 isParatext "false" @default.
- W2599012142 isRetracted "false" @default.
- W2599012142 magId "2599012142" @default.
- W2599012142 workType "article" @default.